Wednesday, March 12, 2025 2:39:14 PM
In other words, we haven't recognized any Revenues from ABBIE yet, and don't anticipate any revenues from ABBIE "Licensing" anytime soon. (Even though last year we forecasted Millions in ABBIE kit Revenues in 2024) Got it.
"Due to the change in strategy, we have been working with our patent legal firm to generate the correct agreements needed for suitable protection." (More delays)
"We have been communicating with both small—and large-scale drug development companies and are currently discussing the validation experiments needed to close the licensing opportunities." (More delays)
____
This is why people are impatient. No Revenues from ABBIE yet, lies about revenue generation, another change in direction...Momentum was not upward, but downward...Management has tanked the pps due to their over-promises, They still can't tell us when anything will result from ABBIE.
Gummies and OTC. That's it for revenues. Guess they had to tell us this before they release a lackluster Annual Report. Frustrating for me, can't speak for anyone else.
We have received some questions about our recent press release and would like to share that we did receive orders for our ABBIE kit. However, our leadership team and our legal advisors identified the risks associated with selling unrestricted ABBIE kits.
— SOHM, Inc. (@sohminc) March 12, 2025
Due to our global patent…
"Due to the change in strategy, we have been working with our patent legal firm to generate the correct agreements needed for suitable protection." (More delays)
"We have been communicating with both small—and large-scale drug development companies and are currently discussing the validation experiments needed to close the licensing opportunities." (More delays)
____
This is why people are impatient. No Revenues from ABBIE yet, lies about revenue generation, another change in direction...Momentum was not upward, but downward...Management has tanked the pps due to their over-promises, They still can't tell us when anything will result from ABBIE.
Gummies and OTC. That's it for revenues. Guess they had to tell us this before they release a lackluster Annual Report. Frustrating for me, can't speak for anyone else.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
